UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (ABT) following Abbott's agreement to acquire Exact Sciences for $105 per share. This acquisition, expected to close in Q2 2026, will expand Abbott's Diagnostics division and venture into cancer care with Exact Sciences' Cologuard test. UBS projects Abbott will outperform competitors in sales and EPS starting in 2026 due to its medical technology profile and double-digit growth.

雅培

<p>瑞士银行重申了对雅培的买入评级和 158 美元的目标价，此次评级是在雅培收购 Exact Sciences 之后做出的，这标志着今年医疗科技行业最大的收购。雅培被认为是一个值得投资的优质慢增长股票</p>

瑞银在雅培实验室（ABT）收购精确科学公司期间重申了买入评级